Compare · JANX vs NVO
JANX vs NVO
Side-by-side comparison of Janux Therapeutics Inc. (JANX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JANX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 222.3x JANX ($823.9M).
- Over the past year, JANX is down 48.5% and NVO is down 45.3% - NVO leads by 3.2 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 1 for JANX).
- NVO has more recent analyst coverage (25 ratings vs 19 for JANX).
- Company
- Janux Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $13.33-1.41%
- $41.26+0.62%
- Market cap
- $823.9M
- $183.15B
- 1M return
- -5.99%
- -10.46%
- 1Y return
- -48.53%
- -45.32%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 1
- 8
- Recent ratings
- 19
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest JANX
- Chief Corp. & Bus. Dev. Ofcr Doyle Janeen Noel sold $56,944 worth of shares (4,059 units at $14.03), decreasing direct ownership by 5% to 75,941 units (SEC Form 4) to satisfy tax liability
- Amendment: SEC Form SCHEDULE 13G/A filed by Janux Therapeutics Inc.
- Vice President, Accounting Dobek Maria sold $28,878 worth of shares (2,038 units at $14.17), decreasing direct ownership by 6% to 32,270 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Janux Therapeutics Inc.
- SEC Form 10-Q filed by Janux Therapeutics Inc.
- Janux Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
- Amendment: SEC Form SCHEDULE 13G/A filed by Janux Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Janux Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Janux Therapeutics Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care